Table 4.
Clinical outcomes in TXA trial
| Outcomes | TXA (N = 49) | Placebo (N = 51) | HR (95% CI) |
|---|---|---|---|
| Composite outcome within 30 days after surgerya, n (%) | 1 (2.0%) | 6 (11.8%) | 0.16 (0.02–1.34) |
| Vascular mortality, n (%) | 0 (0.0) | 1 (2.0)b | |
| Non-fatal myocardial infarction, n (%) | 1 (2.0%) | 3 (5.9%) | |
| Stroke, n (%) | 0 (0.0) | 0 (0.0) | |
| Pulmonary embolism, n (%) | 0 (0.0) | 0 (0.0) | |
| Deep vein thrombosis, n (%) | 0 (0.0) | 1 (2.0) | |
| Life-threatening bleeding, n (%) | 0 (0.0) | 2 (3.9) | |
| Non-fatal major bleeding, n (%) | 0 (0.0) | 1 (2.0) | |
| All-cause mortality, n (%) | 0 (0.0) | 1 (2.0) | –c |
| Myocardial infarction, n (%) | 1 (2.0%) | 4 (7.8%) | 0.23 (0.03–2.07) |
| MINS, n (%) | 0 (0.0%) | 6 (11.8%) | –c |
| Cardiac revascularization, n (%) | 0 (0.0) | 1 (2.0) | –c |
| Postoperative infection, n (%) | 6 (12.2) | 7 (13.7) | 0.77 (0.26–2.30) |
| Postoperative sepsis, n (%) | 1 (2.0) | 4 (7.8) | 0.23 (0.03–2.04) |
| Congestive heart failure, n (%) | 1 (2.0) | 0 (0.0) | –c |
| Re-hospitalization for vascular reason, n (%) | 0 (0.0) | 1 (2.0) | –c |
| Seizure, n (%) | 0 (0.0) | 0 (0.0) | –c |
TXA tranexamic acid, HR hazard ratio, CI confidence interval, MINS myocardial injury after noncardiac surgery
aComposite outcome of vascular mortality, non-fatal myocardial infarction, non-fatal stroke, non-fatal cardiac arrest, non-fatal pulmonary embolism, non-fatal deep vein thrombosis, non-fatal life-threatening bleeding, and non-fatal major bleeding
bDue to myocardial infarction
cNot determinable